Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose 12.78% during previous trade. Morgan Stanley issued rating on the stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in a research note issued to investors on Aug-17-16, the stock received “Upgrade” rating from Equal-Weight to Overweight from $33 to $42. Additionally Mizuho issued their verdict on the stock of the company, on record date of Aug-15-16 the stock was “Upgraded” from Underperform to Neutral from $11 to $25 besides that on Aug-10-16 Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was “Reiterated” by RBC Capital Mkts as Sector Perform from $31 to $36. Furthermore on Aug-10-16 the stock was “Reiterated” by Piper Jaffray as Underweight from $19 to $22.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares ended last trading session at the price of $30.00 whereas a number of traders indicating mean target price will hit $43.78 over the next twelve months, mean value of price target most recently revised on 08/15/16. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s highest estimates of price target are $175.00 and low forecast is $16.00 based on the opinion of 18 analysts. The price target estimates represents a standard deviation of 16.03. However brokerage recommendations suggests an ABR of 2.73 based on calls of 15 experts, where 4 brokers polls the stock a Strong Buy, 0 suggest the stock a Buy, 9 suggest Hold, 0 are rating the stock as Sell while 2 as Strong Sell.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is expected to release the earnings of its current quarter on 10/17/16. The company is expected to release $1.78 EPS for current quarter according to 15 analysts whereas the company reported $2.74 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $1.65 and high estimate of $1.95. For the current year Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has set to release EPS of $6.54 as per the sentiments of 17 analysts, however according to 20 analysts, the company expected to release $7.79 EPS for next year.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s average revenue estimates for the current quarter are 2.51B according to 11 number of analysts. However its lowest revenue estimates are 2.44B and highest revenue estimates are 2.56B. A year ago the company’s sales were 2.79B. Its yearly sales growth estimates are -9.80%. For the next quarter the company has anticipated average revenues of 2.63B, according to the sentiments of 11 analysts. For the current year the company has fixed 9.95B revenues, as per the opinion of 17 analysts. For the current year the company has low revenue estimates of 9.68B in contradiction of high revenue estimates of 10.31B. Whereas for the next year revenues are set at 10.48B by 20 analysts.
The stock exchanged hands 81.24M shares versus average trading capacity of 27.97M shares, while its shares total market worth is $10.24B along with 341.19M outstanding shares. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were trading -88.12% below from the 52-week high price mark of $252.51 and +61.73% above from the 52-week price bottom of $18.55. However the company observed 52 week high price on 09/21/15 and witnessed 52 week low price on 06/27/16. The company’s price sits 30.60% above from its 50-day moving average of $23.35 and -45.93% away from the stock’s 200-day moving average which is $38.51. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s price to sales ratio for trailing twelve month stands at 0.97, whereas its price to book ratio for most recent quarter sits at 1.95. However the company’s price to cash per share for most recent quarter stands at 11.78. Its price to free cash flow for trailing twelve months is 7.71.